Navigation Links
October 2009 Mayo Clinic Women's HealthSource Highlights Ductal Carcinoma In Situ, New Hearing Aid Options and Self-Acceptance
Date:10/24/2009

eatment approach is still being debated.

Lumpectomy or mastectomy: Most women with DCIS are good candidates for a lumpectomy, where a portion of breast tissue is removed. However, there's a slightly higher chance that the cancer will return after a lumpectomy than after a mastectomy, which involves removal of breast tissue, skin, areola and nipple.

Mastectomy is commonly recommended when the area of DCIS is large or in several parts of one breast. Women may choose this option if they can't have or don't want radiation. Some women choose to have both breasts removed to prevent recurrence or a new cancer.

Radiation therapy: Radiation therapy is almost always recommended after a lumpectomy. Research has shown that it significantly reduces the chances that DCIS will recur or progress to an invasive form of cancer. Radiation is usually given five days a week for five to six weeks. Some research has questioned whether this approach is overly aggressive, particularly for older women with small, slow-growing tumors.

Tamoxifen therapy: Tamoxifen is a synthetic hormone that can be used to help treat or prevent the development of breast cancers. It's approved as therapy after surgery or radiation to prevent recurrence of DCIS or a new cancer in the opposite breast. But, some doctors don't recommend it because no evidence shows that tamoxifen improves long-term survival with this type of cancer. Taking tamoxifen can result in side effects such as hot flashes. And tamoxifen may increase the risk of blood clots and cancer of the uterus.

Researchers are attempting to better understand which women with DCIS are at highest and lowest risk of recurrence. That information would help in determining the most appropriate treatment. In the meantime, patients and their care providers should discuss the pros and cons of all treatment approaches.

New Hearing Aid Options: Looking Good
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Stryker To Host Conference Call on October 17, 2007
2. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
3. This October, the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic
4. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
5. NEWSWEEK: Media Lead Sheet: October 1, 2007 Issue (on newsstands Monday, Sept. 24).
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
8. September/October 2007 Annals of Family Medicine tip sheet
9. Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx
10. Kroger Pink Tag Campaign to Raise $2.5 Million for Breast Cancer Awareness in October
11. Optometry Career Conferences Set for Five N.C. Campuses in October
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Cuidado Casero ... and hospice, PCO, PCA, and PHC in Texas, New Mexico, ... a sponsor of the North Texas Chapter of PAM’s 2014 ... the Peruvian American Medical Society. The North Texas chapter was ... and other professionals interested in improving medical care for the ...
(Date:7/27/2014)... 2014 Hyaluronic Acid can hold 1,000 ... key to the power of Hyaluronic Serums. , "Hyaluronic ... founder of Sublime Beauty®. "But like collagen, it diminishes ... ours improves skin moisture-retention and radiance." , Hyaluronic ... a healthy and beautiful look. Key Ingredients in the ...
(Date:7/27/2014)... Detroit, MI (PRWEB) July 27, 2014 ... the public with organic ways to achieve a younger ... eye cream buyer's guide to help men and women ... . , The details that are presented in the ... range of price information for consumers. On drawback to ...
(Date:7/27/2014)... new pill-only antiviral drug regimens could provide shorter, more ... majority of patients infected with hepatitis C, even those ... two studies published in The Lancet . , ... is the most common genotype in the USA, Europe, ... the most difficult to treat. , Around 150 million ...
(Date:7/27/2014)... a powerful drug given at the time of a ... of rejection, but that it also allows a less ... the operation. , The key results are reported in ... Transplant Congress in San Francisco today. They will help ... combinations of treatments used to prevent early kidney rejection ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3
... cause damage to the brain of youngsters, says a ... misuse can do to them. // ,Thomas Heffernan, ... students for the research presented at the British Psychological ... of Daily Mail. ,Half the students ...
... research team from the New York University College of Dentistry ... oral decay evolved along with its human hosts. ... common ancestor who lived in Africa between 100,000 and 200,000 ... by Page Caufield, a professor of cariology and comprehensive care ...
... in EMBO says that the parasite that is responsible ... new pathway. Sleeping sickness is caused by Trypanosoma brucei ... ,Shulamit Michaeli and colleagues describe a pathway in T. ... this pathway shuts down the synthesis of a crucial ...
... the healthcare sector with a super-specialty hospital in Gurgaon,// on ... of Rs.2.1 billion ($45 million). ,Christened Artemis Health ... will open next month. "In the second phase, another 240 ... of AHS. ,"This is the first of similar ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... be hampered if they indulge in excessive drinking.// This ... a psychologist from Northumbria University. ,Alcohol and ... young age which could extend into adulthood. According to ... a very crucial stage. ,Dr. Thomas Heffernan ...
Cached Medicine News:Health News:Tooth Decay Bacteria Evolved Along With Man 2
(Date:7/28/2014)... Germany and LONDON , ... , Collaboration aims to create and commercialize companion diagnostic ... use of IRESSA  for non-small cell lung cancer patients  ... FDA-approved  therascreen   EGFR test and is planned to run on Rotor-Gene ... Project enabled by AstraZeneca master framework agreement ...
(Date:7/25/2014)... July 25, 2014  In today,s marketplace, launching multiple ... challenging - as is managing a portfolio of products ... it possible - or even preferable - to pool ... can you combine resources and activities, and what marketing ... These are just a few of the dilemmas facing ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... new Vice President of Business Development. Peter has been ... a number of different business development positions with some ... were primarily related to business development/sales management and marketing.  ... years makes him a key and strategic asset to ...
Breaking Medicine Technology:QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2
... FALLS, N.J., Dec. 22, 2010 Regenicin, Inc. (OTC Bulletin ... the development of regenerative cell therapies to restore the health ... Annual OneMedForum on January 11-13, 2011 in San Francisco. Randall ... and business model for bringing new regenerative medicine products to ...
... MiMedx Group, Inc. (OTC Bulletin Board: ... patent protected biomaterial-based products, announced today that it has ... leader in the development of tissue processing techniques for ... amnion membranes. Privately held Surgical Biologics was ...
Cached Medicine Technology:Regenicin CEO to Present at OneMedForum Business Development and Finance Conference 2MiMedx Announces Agreement to Acquire Surgical Biologics 2MiMedx Announces Agreement to Acquire Surgical Biologics 3MiMedx Announces Agreement to Acquire Surgical Biologics 4MiMedx Announces Agreement to Acquire Surgical Biologics 5
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
Toothed Pituitary Rongeurs, 12 300 mm....
Ferris Smith Rongeurs, 12 overall length 300 mm....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: